文献类型：期刊文献

英文题名：An Evaluation of HER2-Positive Ovarian Carcinoma Xenografts: From a Novel Therapy to a Noninvasive Monitoring Method

作者：Hong, Zhihui[1];Mao, Xinping[2];You, Jiaxi[1];Liu, Zengli[1];Shi, Yizhen[1]

第一作者：Hong, Zhihui

通信作者：Shi, YZ[1]

机构：[1]Soochow Univ, Affiliated Hosp 2, Dept Nucl Med, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China;[2]GanSu Univ Chinese Med, Div Med Imageol, Lanzhou, Gansu, Peoples R China

第一机构：Soochow Univ, Affiliated Hosp 2, Dept Nucl Med, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China

通信机构：[1]corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Nucl Med, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China.

年份：2018

卷号：33

期号：9

起止页码：411

外文期刊名：CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

收录：;Scopus(收录号：2-s2.0-85056162514);WOS:【SCI-EXPANDED(收录号:WOS:000449296200007)】；

基金：This research was funded by the following grant: SDFEYGJ1104 from the Second Affiliated Hospital of Soochow University, Suzhou, China.

语种：英文

外文关键词：cisplatin; HER2; ovarian carcinoma; single-photon emission computed tomography (SPECT); siRNA

摘要：Purpose: Overexpression of the HER2/neu (HER2) is linked to an adverse outcome in ovarian cancer. Short-interfering RNA (siRNA) is a HER2 inhibitor, which in combination with chemotherapy improves survival rate. The aim of this study was to evaluate the efficacy of adenovirus mediated HER2-siRNA in combination with cisplatin (Ad-HER2-siRNA+DDP) on treating HER2-positive ovarian cancer xenografts and explore the effectiveness of I-131-Herceptin immunoSPECT imaging for monitoring the tumor's progression. Methods: Mice with ovarian cancer xenografts were treated with different therapy regimens and imaged at 1, 4, 8, 12, 24, 48, 72, and 96 h postinjection with I-131-Herceptin. Concurrently, the tumor/background (T/B) ratios were calculated. In addition, HER2 protein expression levels were determined by immunohistochemistry (IHC). Results: The in vivo therapy experiments revealed that tumor weight and volume of Ad-HER2-siRNA+DDP group was the least of all. The IHC results further confirmed that HER2 protein level was significantly downregulated in this group. The results of SPECT imaging showed that the T/B ratios at each time point in Ad-HER2-siRNA +DDP group was the lowest (p < 0.05). Conclusions: The data demonstrate that the growth of xenografts of human ovarian cancer with high expression of HER2 could be inhibited effectively by Ad-HER2-siRNA+DDP. I-131-Herceptin had potential use for noninvasive imaging of HER2 expression.